When was CIPHARM founded?

CIPHARM was founded in 1986 and raised its 1st funding round 28 years after it was founded.

Where is CIPHARM located?

CIPHARM is headquartered in Abidjan, Ivory Coast.

Is CIPHARM a funded company?

CIPHARM is a funded company, having raised a total of $***** in its 1st and only funding round, a PE round on Apr 16, 2014.

When was the latest funding round of CIPHARM?

CIPHARM's latest funding was a $***** PE round on Apr 16, 2014, with participation from 1 investor.

Where does CIPHARM rank among its competitors?

CIPHARM ranks 299th amongst 885 active competitors, of which 28 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Pontika Aerotech, which secured $11.9M in Sep, 2024.

Who are the top competitors of CIPHARM?

CIPHARM's top competitors include Jubilant Life Sciences, Akums and Nivagen Pharmaceuticals. Among them, Pontika Aerotech secured the most recent funding round in September, 2024.

CIPHARM - 2026 Company Profile, Funding & Competitors

Company Details

CIPHARM develops and manufactures finished formulations such as tablets, capsules, syrup, and injectables. The products are of various therapeutic categories including antibiotics, analgesics, antipyretics, anti-infectives, gastrointestinal, antihypertensives, antispasmodics, muscle relaxants, and others.

Website: www.cipharm.ci/
Social
Email ID: *****@cipharm.ci
Phone Number: +225 **********

Key Metrics

Founded Year

1986

Location

Abidjan, Ivory Coast

Stage

Late Stage

Total Funding

$4.21M in 1 round

Latest Funding Round

PE, Apr 16, 2014, $*****

Investors

Cauris Management

Ranked

299^th among 885 active competitors

Similar Companies

Jubilant Life Sciences & 1096 more

View CIPHARM's full profile

CIPHARM has raised a total funding of $4.21M over 1 round. Its latest funding round was a PE round on Apr 16, 2014 for $*****. 1 investor participated in its latest round. CIPHARM has 1 institutional investor.

Here is the list of recent funding rounds of CIPHARM:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 16, 2014	9912039	PE	3650586	3417978	7908563	7907344

Access funding benchmarks and valuations. Sign up today!

View details of CIPHARM's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CIPHARM include Jubilant Life Sciences, Akums and Nivagen Pharmaceuticals. Here is the list of Top 10 competitors of CIPHARM, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jubilant Life Sciences 1978, Noida (India), Public	Company offering a suite of R&D and manufacturing services for small molecules and generics	-	Samena Capital, General Atlantic & 1 others	59/100
2nd	Akums 2004, Delhi (India), Public	CDMO focusing on spectrum of dosage forms and therapeutic segments	$70M	Quadria Capital & 5 others	58/100
3rd	Nivagen Pharmaceuticals 2009, Sacramento (United States), Acquired	Developer and contract manufacturer of generic drugs, tablets, capsules, ointment and solution	$31M	Telegraph Hill Partners, BizCap & 2 others	57/100
4th	Recipharm 1995, Jordbro (Sweden), Acquired	Contract services for pharmaceutical development and manufacturing	-	Ampersand Capital, CPP Investments	54/100
5th	Labiana 1958, Corbera de Llobregat (Spain), Unfunded	Contract laboratory and contract manufacturing services for pharmaceutical and animal health industries	-	-	54/100
6th	Chugai Pharmaceutical 1925, Tokyo (Japan), Acquired	Developer of innovative pharmaceutical products and services	-	Digital Pharma Lab	54/100
7th	Asahi Kasei 1931, Chiyoda-ku (Japan), Public	CDMO focused on manufacturing of liquid, solid & injectable drug formulations	-	Europa	53/100
8th	Pontika Aerotech 2017, Paonta Sahib (India), Series A	Contract manufacturer of formulations	$11.9M	India SME Investments, Vidit Healthcare & 14 others	52/100
9th	Halo Pharma 2006, Hanover (United States), Acquired	CDMO offering integrated drug development services	$25M	Noramco, SK Capital	52/100
10th	Leukocare 2003, Germany, Series B	Developer of proprietary stabilizing and protecting solutions for biologics formulation	$17.5M	Petrichor, LifeCare Partners	52/100
299th	CIPHARM 1986, Abidjan (Ivory Coast), Late Stage	Developer and manufacturer of tablets, capsules, syrup, and injectables	$4.21M	Cauris Management	29/100